Company intelligence / Profile preview

FIRST-MD

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

First-MD is a clinical-stage biotechnology company based in Suzhou, China, focused on the discovery and development of innovative oncology therapeutics. The company's primary research efforts center on small molecule inhibitors and biologics targeting key pathways in cancer cell proliferation and immune evasion. Its lead programs include next-generation CDK4/6 inhibitors designed to treat hormone receptor-positive breast cancer and other solid tumors. First-MD aims to address unmet medical needs in oncology through both internal R&D and strategic collaborations within the global life sciences ecosystem.

Therapeutic areas: Oncology
Modalities: Small moleculeAntibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on FIRST-MD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIRST-MD.

Explore the full profile